As a follow up to The HDA Research Foundation’s First 90 Days report, this report uncovers how the US biopharmaceutical and medical product supply chain adapted to disruptions — and plans to build strategies for the future. The Foundation contracted a third party with deep experience in the healthcare supply operations to explore the challenges the industry has faced over the past three years; the anticipated future disruption landscape; recovery initiatives that the industry has adopted during COVID-19; and potential future strategic opportunities to improve supply chain resiliency, agility and sustainability. The report also shows the initiatives that different supply chain players consider as valuable and likely to be implemented. Findings may have the potential to help players across the healthcare supply chain plot a successful path forward and help achieve their resilience and business objectives.